Envoy Medical (NASDAQ:COCH) has announced that the FDA has approved its Investigational Device Exemption application for the pivotal study of its Acclaim fully implanted cochlear implant. The company asserts that the...
Closely-held Starton Therapeutics has announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance (NOA) for its U.S. patent application covering the company’s continuous delivery...
BioRestorative Therapies (NASDAQ:BRTX) has announced that the Israel Patent Office has issued a Notice of Allowance for a new patent application, covering several fundamental elements of its allogeneic, off-the-shelf...
Appili Therapeutics (TSX:APLI; OTCPink:APLIF) announced that the FDA has provided positive feedback on the development strategy and NDA application for the company’s ATI-1801 for cutaneous leishmaniasis (CL). ATI-1801...
HOOKIPA Pharma (NASDAQ:HOOK) has announced that the first patient has been dosed in an investigator-initiated trial (IIT) of eseba-vec as adjunct therapy for patients with minimal residual disease-positive, HPV-driven...
CalciMedica (NASDAQ:CALC) has announced late-breaking positive data from its Phase 2b CARPO trial of Auxora in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS). The results are to...
Allogene Therapeutics (NASDAQ:ALLO) has announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to its ALLO-316 for treating adult patients with CD70-positive advanced or metastatic...
Shuttle Pharmaceuticals (NASDAQ:SHPH) has announced the successful dosing of the first three patients in its Phase 2 clinical trial of Ropidoxuridine, aimed at treating glioblastoma. Ropidoxuridine, Shuttle’s lead...
Conavi Medical (TSXV:CNVI) has announced that the Journal of the American College of Cardiology: Cardiovascular Interventions (JACC) has published a peer-reviewed article detailing recent advances in hybrid...
PolTREG (WSE:PTG) has launched a Phase 2 clinical trial of PTG-007, a polyclonal autologous Treg cellular therapy, in children with presymptomatic Type-1 diabetes (T1D), following approval from the European Medicines...